Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aprotinin versus tranexamic acid in dual antiplatelet therapy patients undergoing on-pump cardiac surgery
NL-OMON49829Phase 2Recruiting
- Sponsor
- Isala
- Start
- Nov 2020
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of aprotinin and tranexamic acid in coronary arteriosclerosis and Cardiac valve disease (VHD) (2 arms), sponsored by Isala. Primary endpoint: Postoperative blood loss at 12 hours. Started Nov 2020; status: recruiting.
02
Drugs
aprotinintranexamic acid
03
Conditions
coronary arteriosclerosisCardiac valve disease (VHD)
Beyond the preview
Go deeper on NL-OMON49829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49829.